Thomas J George Selected Research

Rectal Neoplasms (Rectal Cancer)

7/2023	Preoperative Treatment of Locally Advanced Rectal Cancer.
10/2021	Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma.
8/2021	Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
1/2021	A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy.
12/2020	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
12/2018	Objective Preoperative Parameters Predict Difficult Pelvic Dissections and Clinical Outcomes.
1/2018	Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management.
1/2018	Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.
1/2018	Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.
10/2016	NRG GI002: Moving the needle toward TNT in locally advanced rectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas J George Research Topics

Disease

70	Neoplasms (Cancer) 04/2024 - 11/2007
19	Pancreatic Neoplasms (Pancreatic Cancer) 09/2023 - 11/2007
18	Adenocarcinoma 12/2023 - 12/2009
15	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 08/2014
14	Colonic Neoplasms (Colon Cancer) 11/2022 - 01/2015
13	Rectal Neoplasms (Rectal Cancer) 07/2023 - 06/2010
7	Neoplasm Metastasis (Metastasis) 02/2024 - 01/2015
6	Circulating Neoplastic Cells 07/2023 - 01/2017
5	Disease Progression 02/2024 - 08/2014
4	Cachexia 12/2023 - 01/2017
3	Residual Neoplasm 10/2022 - 12/2020
3	Microsatellite Instability 10/2022 - 11/2016
2	Weight Loss (Weight Reduction) 12/2023 - 01/2018
2	Cancer Pain 09/2023 - 01/2018
2	Diarrhea 01/2021 - 06/2010
2	Neutropenia 01/2021 - 08/2014
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2011 - 02/2010
2	Melanoma (Melanoma, Malignant) 01/2010 - 03/2008
1	Gallbladder Neoplasms (Gallbladder Cancer) 02/2024
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2023
1	Fatigue 07/2023
1	Ovarian Epithelial Carcinoma 01/2023
1	Asthma (Bronchial Asthma) 01/2023
1	Adenosquamous Carcinoma 12/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2022
1	Turcot syndrome 10/2022
1	Death (Near-Death Experience) 01/2022
1	Anemia 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Infections 01/2021
1	Leukopenia 01/2021
1	Liver Neoplasms (Liver Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2023 - 05/2013
8	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2023 - 10/2017
8	Fluorouracil (Carac)FDA LinkGeneric 09/2023 - 08/2017
5	Immune Checkpoint InhibitorsIBA 11/2022 - 08/2018
5	Capecitabine (Xeloda)FDA Link 10/2022 - 06/2010
4	Monoclonal AntibodiesIBA 07/2023 - 03/2010
4	Cetuximab (Erbitux)FDA Link 01/2021 - 03/2010
4	Gemcitabine FDA Link 01/2018 - 11/2007
3	Opioid Analgesics (Opioids)IBA 04/2024 - 01/2018
3	Trinitrotoluene (TNT)IBA 10/2023 - 10/2016
3	Irinotecan (Camptosar)FDA LinkGeneric 09/2023 - 08/2014
3	ErbB Receptors (EGF Receptor)IBA 07/2023 - 03/2010
3	Circulating Tumor DNAIBA 10/2022 - 01/2022
3	Interleukin-8 (Interleukin 8)IBA 01/2017 - 10/2015
2	NivolumabIBA 02/2024 - 11/2019
2	IpilimumabIBA 02/2024 - 11/2019
2	AntigensIBA 12/2023 - 01/2023
2	CarbohydratesIBA 12/2023 - 01/2023
2	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 09/2023 - 01/2018
2	durvalumabIBA 07/2023 - 01/2019
2	Phosphotransferases (Kinase)IBA 01/2023 - 11/2016
2	sotorasibIBA 01/2023 - 01/2022
2	Leucovorin (Folinic Acid)FDA Link 10/2022 - 01/2018
2	Sodium Glutamate (Accent)IBA 11/2021 - 01/2021
2	pembrolizumabIBA 08/2021 - 11/2019
2	AntibodiesIBA 03/2020 - 11/2016
2	BuffersIBA 01/2020 - 01/2014
2	Bevacizumab (Avastin)FDA Link 01/2019 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2015
2	Interleukin-6 (Interleukin 6)IBA 01/2017 - 01/2017
2	Trastuzumab (Herceptin)FDA Link 04/2016 - 01/2015
2	InterferonsIBA 12/2015 - 01/2010
1	RNA (Ribonucleic Acid)IBA 12/2023
1	EnzymesIBA 09/2023
1	GoldIBA 07/2023
1	SteroidsIBA 01/2023
1	Tumor Biomarkers (Tumor Markers)IBA 01/2023
1	adavosertibIBA 01/2023
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2022
1	atezolizumabIBA 11/2022
1	tivozanibIBA 11/2022
1	FicollIBA 07/2022
1	Cell-Free Nucleic AcidsIBA 03/2022
1	Metformin (Glucophage)FDA LinkGeneric 01/2022
1	adagrasibIBA 01/2022
1	Algenpantucel-LIBA 01/2022
1	Cancer VaccinesIBA 01/2022
1	src-Family KinasesIBA 10/2021
1	Dasatinib (BMS 354825)FDA Link 10/2021
1	neratinibIBA 01/2021
1	AndrogensIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	trifluridine tipiracil drug combinationIBA 01/2021
1	Panitumumab (Vectibix)FDA Link 01/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021

Therapy/Procedure

43	Therapeutics 02/2024 - 11/2007
27	Drug Therapy (Chemotherapy) 02/2024 - 02/2010
13	Neoadjuvant Therapy 10/2023 - 01/2015
8	Radiotherapy 10/2017 - 12/2009
6	Adjuvant Chemotherapy 11/2022 - 10/2017
5	Immunotherapy 11/2022 - 01/2010
3	Lab-On-A-Chip Devices 01/2023 - 01/2017
2	Treatment Delay 01/2021 - 01/2017
2	Precision Medicine 01/2018 - 01/2016
2	Pancreaticoduodenectomy 01/2017 - 01/2016
1	Chemoradiotherapy 07/2023
1	Continuity of Patient Care 06/2022